U.S. biotech firm Horizon Therapeutics was among the top global performers last week, with its stock soaring nearly 21% for the week. The company, which produces treatments for people with autoimmune and severe inflammatory diseases, reported earnings last week. It raised its full-year 2022 net sales guidance to a range of between $3.59 billion and $3.61 billion. Its previous range was $3.53 billion to $3.6 billion. Analysts covering the stock are positive on its future performance, with nearly 87% giving it a "buy" rating and price target upside of 36%, according to FactSet. The stock was trading around $77 as...